iSpecimen (ISPC) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OmniAb is the larger company by market cap ($679.7 million vs $2.6 million), about 257.3 times the size. OmniAb converts more of its revenue into profit, with a net margin of -347.0% versus -543.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ISPC | OABI |
|---|---|---|
| Share price | $0.4563 | $4.66 |
| Market cap | $2.64M | $679.71M |
| 1-day change | -13.58% | -7.36% |
| YTD return | — | +151.89% |
| 1-year return | — | +163.28% |
| 5-year return | — | -53.40% |
| EPS (TTM) | $-52.98 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.93M | $18.67M |
| Revenue growth (YoY) | -79.24% | -29.27% |
| Net income (latest FY) | $-10.49M | $-64.78M |
| Gross margin | 11.18% | — |
| Operating margin | -465.42% | -369.49% |
| Net margin | -543.68% | -347.04% |
| 52-week high | $27.44 | $5.45 |
| 52-week low | $0.432 | $1.35 |
| Distance from 52-week high | -98.34% | -14.50% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +78.76% |
| Average volume | 598.66K | 1.46M |
| Shares outstanding | 5.79M | 145.86M |
| Employees | 7 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OmniAb is about 257.3 times larger than iSpecimen by market value ($679.71M vs $2.64M).
- OmniAb is more profitable, keeping -347.0 cents of every revenue dollar as net income versus -543.7 cents for iSpecimen.
- OmniAb grew revenue faster in its latest fiscal year (-29.27% vs -79.24%).
About iSpecimen
ISPC stock →iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 7 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
ISPC vs OABI FAQ
Which is bigger, iSpecimen or OmniAb?
OmniAb (OABI) is larger, with a market capitalization of $679.71M compared with $2.64M for iSpecimen (ISPC).
Are iSpecimen and OmniAb in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.